Inclusion Criteria:
* Participant must be 18 to 50 years of age inclusive
* Participants who are generally healthy as determined by medical evaluation based on screening medical history, physical examination, laboratory tests, and cardiac monitoring
* Body weight of at least 50.0 kilogram (kg) for male participants or at least 45.0 kg for female participants
* Body mass index (BMI) within the range of 18.0 to 28.0 kilogram per square meter (kg/m\^2) (inclusive)
* Capable of giving signed informed consent
* Males and females of non-childbearing potential•
Exclusion Criteria:
* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data
* A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug
* Abnormal blood pressure (as determined by the investigator)
* Symptomatic herpes zoster within 3 months prior to screening
* Significant allergies to humanized monoclonal antibodies
* Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions
* Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
* Breast cancer within the past 10 years
* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* A clinically significant abnormality in the average of triplicate 12-lead ECG readings performed at screening including
* Antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal therapy within 30 days of dosing
* Past or intended use of over the counter or prescription medication (including herbal medications) within 7 days prior to dosing and for the duration of study participation
* Live vaccine(s) within 30 days prior to screening or plans to receive such vaccines during the study
* Treatment with biologic agents within 12 weeks, 5 half-lives or twice the duration of the biological effect of the biologic agent (whichever is longer) prior to dosing
* Participation in other clinical study that resulted in loss of blood or blood products \>500 millilitres (mL) within a 56 days before participation in this study
* Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day
* Current enrolment or past participation in another investigational study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered prior to the first dosing day: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer)
* Current enrolment or past participation in this clinical study
* A positive confirmation of SARS-CoV-2 infection at pre-dose
* Evidence of active or latent Tuberculosis (TB)
* Positive hepatitis Bor hepatitis C test at screening or within 3 months prior to study intervention.
* Positive prestudy drug/alcohol test
* An average weekly intake of \>14 units of alcohol
* Regular use of known drugs of abuse, including Tetrahydrocannabinol (THC)
* Current smoker or user or tobacco- or nictotine- containing products, within 30 days prior to screening visit
* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study
* Any products intended to treat medical conditions that are not approved by the governing health authority (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc)
* The participant has a phobia to needles
